Menovag

Estradiol, the active ingredient in Menovag, is an estrogen presented as a vaginal formulation for local use. It treats vaginal atrophy and other estrogen‑deficiency symptoms in post‑menopausal women.

GNH USA supplies Menovag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Estradiol, an estrogen used in hormone replacement therapy, addresses conditions related to estrogen deficiency.

- Vaginal atrophy: improves vaginal mucosal health and reduces dryness. - Menopausal symptoms: alleviates urogenital discomfort and hot flashes. - Estrogen deficiency: restores local estrogen levels to support tissue integrity.

Estradiol administered vaginally may be associated with a range of adverse reactions.

Common Side Effects: - Vaginal irritation or burning - Increased vaginal discharge - Itching or pruritus - Mild headache - Breast tenderness - Nausea

Serious or Rare Side Effects: - Endometrial hyperplasia or bleeding - Thromboembolic events (e.g., deep vein thrombosis) - Severe allergic reaction (anaphylaxis) - Uterine cancer risk with prolonged use - Unexplained vaginal bleeding

Before initiating Menovag, several precautionary measures should be considered. - Contraindications: avoid use in women with known estrogen‑dependent neoplasms. - Cardiovascular risk: assess history of thromboembolic disease. - Breast health: perform regular examinations and imaging as indicated. - Duration: use the lowest effective dose for the shortest period required. - Monitoring: schedule follow‑up visits to evaluate symptom relief and adverse effects. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Estradiol can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Warfarin: increased risk of bleeding. - Combined estrogen‑containing contraceptives: additive estrogen effect may raise thrombotic risk. - Tamoxifen: antagonistic action may reduce therapeutic benefit.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise estradiol levels. - CYP3A4 inducers (e.g., phenytoin, rifampin): may lower estradiol effectiveness. - SSRIs (e.g., fluoxetine): may diminish relief of vasomotor symptoms.